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Abstract
Modified-live herpesvirus vaccines are widely used in humans and animals, but field strains
can emerge that have a higher virulence and break vaccinal protection. Since the introduc-
tion of the first vaccine in the 1970s, Marek’s disease virus overcame the vaccine barrier by
the acquisition of numerous genomic mutations. However, the evolutionary adaptations in
the herpesvirus genome responsible for the vaccine breaks have remained elusive. Here,
we demonstrate that point mutations in the multifunctional meq gene acquired during evolu-
tion can significantly alter virulence. Defined mutations found in highly virulent strains also
allowed the virus to overcome innate cellular responses and vaccinal protection. Concomi-
tantly, the adaptations in meq enhanced virus shedding into the environment, likely provid-
ing a selective advantage for the virus. Our study provides the first experimental evidence
that few point mutations in a single herpesviral gene result in drastically increased virulence,
enhanced shedding, and escape from vaccinal protection.
Author summary
Viruses can acquire mutations during evolution that alter their virulence. An example of a
virus that has shown repeated shifts to higher virulence in response to more efficacious
vaccines is the oncogenic Marek’s disease virus (MDV) that infects chickens. Until now, it
remained unknown which mutations in the large virus genome are responsible for this
increase in virulence. We could demonstrate that very few amino acid changes in the meq
oncogene of MDV can significantly alter the virulence of the virus. In addition, these
changes also allow the virus to overcome vaccinal protection and enhance the shedding
into the environment. Taken together, our data provide fundamental insights into evolu-
tionary changes that allow this deadly veterinary pathogen to evolve towards greater
virulence.
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Introduction
Vaccines have revolutionized modern medicine and industrial animal farming by dramatically
lowering disease incidence and mortality [1,2]. While vaccines are ideal interventions for erad-
ication, some viruses can evolve to overcome vaccinal protection [3]. Therefore, it is crucial to
understand the evolutionary changes that facilitate vaccine resistance in order to develop more
effective vaccines. [4]. A well-documented example of virus evolution towards a greater viru-
lence is the highly oncogenic Marek’s disease virus (MDV) [5,6]. MDV is an alphaherpesvirus
that infects chickens and is controlled by the wide application of modified live virus vaccines.
In the absence of vaccination, infected chickens typically develop an acute rash, and edematous
neuronal and brain damage, severe lymphomas, paralysis, and death at a very young age [7,8].
The tumors induced by MDV are considered to be one of the most frequent cancers in the ani-
mal kingdom [9].
MDV has undergone three major shifts in virulence over the past decades (Fig 1A). This
evolution resulted in ever more virulent field strains that cause increased severe clinical symp-
toms and vaccine evasion [8,10,11]. MDV strains are currently classified into four pathotypes
based on their pathogenicity in vaccinated and unvaccinated chickens [8,12,13]. First-genera-
tion MDV vaccines, such as the related herpesvirus of turkey (HVT), were introduced in the
1970s to prevent chickens from emerging virulent MDV (vMDV) strains [14]. Soon after the
introduction of the HVT vaccine, very virulent (vvMDV) strains emerged that were more
pathogenic, immunosuppressive, and were able to overcome this vaccinal protection [15]. Pro-
tection against vvMDV was achieved using a second-generation bivalent vaccine, composed of
a combination of a non-oncogenic, related herpesvirus of chickens (MDV-2, strain SB1) with
HVT that protected chickens from clinical disease [14]. Subsequently, very virulent plus (vv
+MDV) strains emerged that are controlled by the third-generation vaccine (CVI988/Ris-
pens); however, it remains unknown if more virulent strains will arise in the future (Fig 1A)
[14,16]. This stepwise evolution of MDV directly correlates with the introduction of MD vac-
cines [17], suggesting that the ‘leaky’ MDV vaccines that protect from disease but are unable to
provide sterilizing immunity may have directly contributed to the increase in virulence [18].
A large number of MDV field strains from all pathotypes have been sequenced over the
years to identify mutations that could be responsible for changes in virulence [19,20]. A few
defined point mutations in the coding sequence of the major MDV oncogene meq have been
identified that coincide with increased virulence (Fig 1A) [10,20]; however, their contribution
in the evolution of MDV towards a greater virulence has never been proven.
Meq is a 339 amino acid basic leucine zipper protein (bZIP) that is expressed in lytically
and latently infected cells, and is encoded in the internal and terminal repeat regions of the
MDV genome [21]. Meq regulates viral and cellular genes by forming heterodimers with other
bZIP proteins such as c-Jun to promote transcription [22]. In addition, Meq can form homodi-
mers that repress the expression of numerous genes [22–25]. The C-terminus of meq encodes
a transactivation domain characterized by proline-rich repeats (PRR) [26]. Low virulent
vMDV strains (e.g. JM/102W) contain five PRR in their C-terminus, whereas vvMDV (e.g.
RB-1B) and vv+MDV strains (e.g. N-strain) possess only three PRR (Fig 1A) [27].
In this study, we set out to determine if these point mutations acquired in meq through the
years contribute to the increase in MDV virulence, vaccine resistance and virus transmission.
The meq isoforms of different pathotypes (vMDV, vvMDV, vv+MDV and the CVI988/Rispens
vaccine strain) were individually inserted into the very virulent RB-1B strain, thereby replacing
its original meq gene. Virus replication was not significantly affected in vitro and in vivo. How-
ever, insertion of less virulent meq isoforms (vacMeq and vMeq) either abrogated or severely
impaired MDV pathogenesis while higher virulent meq isoforms (vvMeq and vv+Meq) readily
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caused disease and tumors. Even in vaccinated chickens, viruses harboring the higher virulent
meqs caused disease and efficiently shed into the environment. Strikingly, only viruses harbor-
ing the vv+Meq were able to overcome vaccinal protection and cause tumors in vaccinated
animals. Furthermore, we show that the point mutations in meq isoforms of higher virulent
MDV strains help the virus to overcome innate cellular responses, potentially contributing to
vaccine failure. Overall, our data show that the evolutionary adaptations in meq substantially
Fig 1. Characterization of the recombinant viruses in vitro. (A) A schematic illustration of the evolution of MDV
towards increased virulence in the context of the indicated vaccine generations. (B) The representation of the Meq
protein with its domains. The N-terminal region comprises of a proline/glutamine (Pro/Gln) rich domain followed by
the basic region and the leucine zipper (ZIP). (C) Virus replication was assessed by multi-step growth kinetics. Mean
viral genome copies per one million cells are shown for the indicated viruses and time points (p>0.05, Kruskal–Wallis
test, n = 3). (D) Plaque size assays of indicated recombinant viruses. The mean plaque diameters of three independent
experiments are shown as box plots with minimums and maximums (p>0.05, one-way ANOVA, n = 150). (E) The
meq expression levels in infected CEC were assessed by RT-qPCR. Meq expression is shown relative to one million
copies of the cellular glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and were not statistically different
(Kruskal-Wallis test). (F) RT-PCR analysis of the meq/vIL8 splice variant using primers specific for the donor site “D”
in meq and the acceptor sites “A” in vIL8. GAPDH was used as a control.
https://doi.org/10.1371/journal.ppat.1009104.g001
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contribute to the increased virulence, vaccine resistance, and enhanced transmission–therefore
playing a central role in the evolution of this highly oncogenic alphaherpesvirus.
Results
Generation of recombinant viruses
To determine if the point mutations in the meq isoforms contribute to MDV evolution
towards a greater virulence, we replaced the meq gene in the very virulent RB-1B MDV strain
with the meqs from different pathotypes as described previously [28]. Briefly, the meq gene
from the CVI988/Rispens vaccine strain, JM/102W (vMDV), RB-1B (vvMDV) or N-strain (vv
+MDV) were inserted into a virus lacking the meq gene (Δmeq) [28] by two-step Red-medi-
ated mutagenesis [29,30]. The insertion of meq isoforms were confirmed by next-generation
sequencing (S2A Fig). The recovered recombinant viruses were termed vacMeq, vMeq, vvMeq
and vv+Meq. Sequencing of the recombinant viruses, passage level 4, confirmed the presence
of the respective meq isoforms in the TRL and IRL without any secondary mutations in the
genome (S2B Fig) or in the meq genes (S2 Table).
Characterization of recombinant viruses in vitro
To determine if the meq isoforms of different pathotypes affect virus replication, we performed
plaque size assays and demonstrated that all viruses efficiently replicated in vitro, while minor
changes were observed that were not statistically significant. The meq genes from less virulent
strains slightly enhanced replication in vitro (Fig 1C), a phenotype also observed with the cor-
responding parental strains [31]. We confirmed this phenotype by plaque size assays (Fig 1D),
underlining that the insertion of meq isoforms only mildly affects MDV replication. We veri-
fied that all meq isoforms are expressed at comparable levels by performing RT-qPCR on sam-
ples from infected chicken embryo cells (CEC) (Fig 1E). Furthermore, we analyzed whether
the splice variant of meq to exons II and exons III of vIL8 (meq/vIL8) is affected through the
differences in meq. Our data revealed the meq/vIL8 splicing is not affected in CEC and CU91
T cells (Fig 1F), which is consistent with the absence of changes in the splice sites.
Role of the meq isoforms in MDV pathogenesis
To investigate if the evolutionary acquired point mutations in the meq gene contribute to
MDV-induced pathogenesis and tumor formation, one-day old unvaccinated chickens were
infected subcutaneously with 4,000 pfu of the respective recombinant viruses. To determine
the effect of the meq isoforms on MDV replication, we quantified viral genome copies in the
blood of infected animals by qPCR. All viruses efficiently replicated in infected animals (Fig
2A), indicating that the changes in the meq isoforms only have a minor contribution to lytic
replication in vivo. We monitored the animals for clinical disease symptoms and tumors dur-
ing the experiment. Replacement with the MDV vaccine meq isoform completely abrogated
virus-induced pathogenesis and tumor formation (Fig 2B and 2C). Viruses harboring the
vMDV meq isoform only induced clinical disease in 20% of the animals, while only 10% devel-
oped gross tumors (Fig 2B and 2C). vvMeq and vv+Meq efficiently induced disease and
tumors, while the native vvMeq resulted in the highest virulence (Fig 2B and 2C).
To assess the effect of the meq isoforms on tumor dissemination, the number of visceral
organs with macroscopic tumors were quantified during necropsy throughout the course of
the experiment and at the day of final necropsy (86 dpi). Replacement with the vMDV meq
severely impaired tumor dissemination (Fig 2D), as only a single organ (spleen) was affected
in each tumor-bearing animal. vvMeq and vv+Meq induced efficient tumor dissemination in
PLOS PATHOGENS Unravelling vaccine breaks of a herpesvirus
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1009104 December 11, 2020 4 / 20
contrast to the lower virulent meq isoforms (Fig 2D). The data of this in vivo experiment was
validated in an independent animal experiment using a different chicken line. In this second
animal experiment, we observed a comparable MD incidence and tumor incidence (S1 Fig).
To ensure that the viruses did not develop compensatory mutations in the animals, we per-
formed next-generation sequencing on viruses derived from organs and tumors (n = 12). Most
viruses did not acquire any mutations in the animals, while three viruses had a single mutation
that was either silent or in a non-coding region (S2C Fig). In addition, we confirm that the
meq was not altered in the host (S2C Fig). These experiments revealed that the mutations in
the meq isoforms affect virus-induced pathogenesis, tumor formation, and dissemination.
Natural spread and pathogenesis of recombinant viruses in contact animals
To confirm that these effects are also observed upon the natural spread of the virus via the
respiratory tract, we co-housed naïve chickens with the subcutaneously infected animals. All
meq isoform viruses were readily transmitted to the contact chickens as viral copies were
detected in the blood (Fig 3A), but only viruses harboring the vv and vv+ meq isoforms caused
disease (Fig 3B). Insertion of meq isoforms from the CVI988/Rispens vaccine and vMDV
pathotypes completely abrogated tumor formation (Fig 3C). Viruses harboring the vvMDV
Fig 2. Influence of meq isoforms from various pathotypes on MDV pathogenesis. (A) MDV genome copies were detected in the blood samples of chickens
infected with indicated viruses by qPCR. Mean MDV genome copies per one million cells are shown for the indicated time points (p>0.05, Kruskal-Wallis
test). (B) Disease incidence in chickens infected with indicated recombinant viruses and significant differences in comparison to vvMeq (�� p<0.0125, Log-
rank (Mantel-Cox) test). (C) Tumor incidence as percentage of animals that developed tumors during the experiment. Asterisks indicate significant differences
compared to vvMeq (� p<0.05 and �� p<0.0125; Fisher’s exact test). (D) Tumor distribution is shown as the number of tumorous organs in tumor-bearing
animals with standard deviations (� p<0.05 and �� p<0.0125; Fisher’s exact test).
https://doi.org/10.1371/journal.ppat.1009104.g002
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and vv+MDV meq isoforms both efficiently induced tumors in the contact animals. As
observed in the subcutaneously infected animals, tumor dissemination of the vv+Meq was
slightly enhanced, although not statistically different, compared to the very efficient vvMeq
(Fig 3D).
Our data demonstrate that the few point mutations in the meq gene directly contribute to
MDV virulence in experimentally and naturally infected animals.
Pathogenesis of meq isoforms in vaccinated animals
Next, we determined if the different meq isoforms contribute to vaccine resistance and affect
virus shedding in vaccinated animals. One-day old chickens were vaccinated subcutaneously
with 4,000 pfu of the commonly used HVT vaccine. At seven days post-vaccination, we
infected all vaccinated chickens with 5,000 pfu of the respective recombinant viruses to deter-
mine if meq contributes to vaccine breaks. Replication of the recombinant viruses (Fig 4A)
and HVT vaccine (Fig 4B) was not statistically different between the groups. Vaccination
completely protected chickens from the less virulent meq isoform viruses (vacMeq and vMeq;
Fig 4C). On the other hand, the higher virulent meq isoform viruses were able to overcome the
Fig 3. Pathogenesis and tumor incidence in naïve contact animals. (A) qPCR analysis of blood samples from naive chickens where MDV genome copies
were determined (p>0.05, Kruskal-Wallis test). (B) Disease incidence in naïve chickens infected via the natural route and tumor incidence (C) and tumor
distribution (D) are shown for co-housed contact animals. Asterisks (�� p<0.0125; Fisher’s exact test) indicate the significant differences in (C).
https://doi.org/10.1371/journal.ppat.1009104.g003
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vaccinal protection and caused disease (vvMeq and vv+Meq; Fig 4C). Strikingly, insertion of
the vv+Meq isoform strongly enhanced virulence in vaccinated animals (Fig 4C). Only chick-
ens infected with vv+Meq developed tumors (Fig 4D), indicating that the few point mutations
in meq allow the virus to overcome the vaccinal protection and cause tumors in vaccinated
animals.
Role of meq isoforms in virus shedding from vaccinated animals
Efficient virus shedding plays an essential role in virus evolution. During infection, MDV is
transported to the feather follicle epithelia in the skin, where it is shed with the feathers into
the environment [32].To assess if the meq isoforms also affect virus shedding, we collected
feathers and dust during the experiment and measured MDV copy numbers by qPCR (Fig 4E
and 4F). Even though all viruses reached the feather follicles at approximately ten days post-
infection (dpi), virus load was significantly increased in viruses harboring vvMeq and vv+Meq
Fig 4. Pathogenesis and shedding of different meq isoform viruses in vaccinated chickens. Viral genome copy
numbers of (A) the meq isoform viruses and (B) the HVT vaccine detected in blood of vaccinated chickens infected
with the meq isoform viruses (p>0.05, Kruskal-Wallis test). (C) Disease incidence and (D) tumor incidence in
vaccinated chickens infected with indicated recombinant viruses. Asterisks (�� p<0.0125, Fisher’s exact test) indicate
statistical differences to vv+Meq in (D). (E) Viral copies from feathers of the meq recombinant viruses. (A), (B) and
(E): mean MDV genome copies per one million cells are shown for the indicated time points. (F) Viral copies per μg of
dust are shown for each group as validated previously [32]. Statistical differences in the feathers and dust samples are
displayed as a comparison to vvMeq. Asterisks indicate significant differences (� p<0.05 and �� p<0.0125; Tukey’s
multiple comparisons test).
https://doi.org/10.1371/journal.ppat.1009104.g004
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(Fig 4E). In addition, shedding was significantly higher upon infection with the vvMeq and
vv+Meq viruses (Fig 4F), indicating that these mutations provide an evolutionary advantage
due to the higher virus levels in the environment. Taken together, we could demonstrate that
few mutations in meq contribute to a higher virulence, allow the virus to overcome vaccinal
protection and enhance virus shedding.
Mutations in meq allow the virus to overcome cellular innate responses
To determine if the specific mutations in meq affect innate immune responses, we stimulated
primary chicken T cells with innate immune agonists (Poly I:C, LPS and cGAMP) and infected
these cells with the different recombinant viruses. Upon infection, we measured the effect of
these innate immune agonists on virus spread to CEC and subsequent virus replication (Fig 5).
Poly I:C, LPS, and cGAMP treatments in general significantly decreased the number of plaques
(Fig 5A), and the plaque sizes (Fig 5B) compared to the media control. Strikingly, viruses har-
boring the higher virulent meq isoforms (vv and vv+Meq) formed significantly more plaques
than the ones with lower virulent isoforms (Fig 5A). Consistently, CEC infections with higher
virulent meq isoform viruses led to increased plaque sizes compared to vacMeq and vMeq (Fig
5B). These results indicate that the mutations in the higher virulent meqs allow the virus to
overcome innate cellular responses induced by these agonists and provide a potential explana-
tion for the vaccine breaks mediated by meq [33].
Discussion
MDV strains have repeatedly increased in virulence and overcame vaccinal protection [34,35].
Virulence is a complex trait and several virulence factors act alone or orchestrated with each
other to drive pathogenesis and tumor formation. These factors include the oncoprotein Meq,
the viral telomerase RNA (vTR), the virus-encoded chemokine vIL-8/vCXCL13, RLORF4,
RLORF5a, pp14, pp38 and telomere arrays present at the ends of the virus genome [6,36]. In
this study, we determined the contribution of meq isoforms alone in MDV pathogenicity,
oncogenicity, and shedding in unvaccinated and vaccinated animals. We provide the first
experimental evidence that distinct polymorphisms in the meq have a substantial impact on
the evolution of MDV towards greater virulence. Our data revealed that only four amino acid
changes (AKQV) are involved in an increase in tumor incidence by more than 50% in our
experiments.
Fig 5. Efficiency of meq isoform viruses to overcome innate immune responses. Primary T cells were activated by
innate immunity agonists (Poly I:C, LPS, or cGAMP). Activated T cells were infected with the different meq isoform
viruses to determine the effects on virus shedding and replication. (A) Plaque counts were performed on CEC overlaid
with 1,000 activated infected primary T cells. (B) Corresponding changes in plaque sizes on infected CEC (normalized
to vvMeq). Asterisks indicate significant differences (� p<0.05 and �� p<0.0125; Tukey’s multiple comparisons test).
https://doi.org/10.1371/journal.ppat.1009104.g005
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We first evaluated the growth properties of the meq isoforms in vitro and in vivo to deter-
mine if meq isoforms from different pathotypes affect virus replication. The meq isoforms did
not differ in their replication properties in tissue culture and in the host. Even though Meq is
expressed during lytic infection, these few mutations in meq do not provide an advantage for
its replication properties. Consistently, Lupiani and colleagues previously demonstrated that
meq is dispensable for virus replication [21]. We demonstrate that the minor mutations resid-
ing in the meq isoforms did not affect meq expression in primary CEC (Fig 1E). In addition to
the Meq protein, alternative splicing gives rise to a splice form with exon 2 and 3 of vIL-8, des-
ignated as meq/vIL8 [37]. We assessed the expression of this splice variant by qRT-PCR in
both CEC and CD4 T cells, revealing that these minor changes in meq do not affect meq/vIL8
splicing (Fig 1F). This is consistent with a previous study that showed that splice variants did
not differ between different pathotypes in infected primary chicken B cells [38]. The compara-
ble expression of meq/vIL8 likely due to the absence of mutation in the splice donor site
encoded in the leucine zipper domain in the meq isoforms, while the branch point and accep-
tors sites are outside of meq and were not altered in our study.
Deletion of meq led to an abrogation of tumor formation, indicating that meq has essential
transforming properties [39]. The observed increase in virulence of strains over the years has
been characterized by the ability to induce lymphoproliferative lesions [13] and an increase in
shedding [5], thereby shifting our focus towards these aspects and the contribution of meq.
In the first animal experiment, we infected one-day-old chickens with viruses harboring
meq isoforms from different pathotypes to determine their individual contribution to virus-
induced pathogenesis and oncogenesis in vivo. In this experiment, we also co-housed the
infected with naïve contact chickens to measure the horizontal spread via the natural route of
infection. The meq gene from the lowest virulence class, vacMeq, completely abrogated MDV
pathogenicity and tumor formation. It has been previously shown that the meq isoform of the
CVI988/Rispens vaccine, is a weaker transactivator, decreasing the expression of cellular and
viral genes due to mutations in the DNA binding domain at positions 71 and 77 (Fig 1A) [40].
Meq binds to its own promoter and through its weak transactivation properties on its own
promoter it could alter the development of T cell tumors. However, we did not observe a
reduction in vacMeq expression on our experiments. The two point mutation differences in
vacMeq ultimately rendered the very virulent RB-1B strain apathogenic (Fig 2). Insertion of
the vMDV meq into RB-1B reduced disease incidence and tumor incidence in infected chick-
ens. The vMDV meq (JM/102W) harbors a 177 bp insertion or duplication of a proline-rich
(PRR) domain [40] located in the transactivation domain (Fig 1A). This insertion increased
the copy number of the PRR, which exerts a transrepression effect [41,42]. The higher virulent
forms vvMeq and vv+Meq showed higher disease incidence rates and enhanced oncogenesis
compared to the less virulent pathotypes (Fig 2B–2D). An independent animal experiment
using a different chicken line confirmed the markedly elevated disease incidence (S1A Fig)
and the higher oncogenic potential for the higher virulent meq isoform viruses (S1B Fig). The
vv+Meq had a slightly lower disease incidence than vvMeq (Figs 2B and S1A). This could be
due to epistatic effects, where the fitness of the virus is impacted not by meq alone, but by its
interaction with the rest of the viral genome. Interestingly, this effect was not detected upon
natural infection in contact animals (Fig 3B). Kumar and colleagues previously inserted meq of
RB-1B into rMd5 (both vv strains), in which the meq only differs in three amino acid positions.
This exchange altered the phenotype of the resulting virus in the subtle way and allowed the
establishment of tumors cell lines (UD36-38) which could not be achieved with the parental
rMd5 [41]. Tumors induced by the recombinant virus showed similar cellular expression pro-
files to rMd5 tumors, suggesting that the context of the strain encoding the Meq protein plays
an important role in pathogenesis. Potential epistatic effects are a limitation in our study and it
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remains to be addressed whether different backbones expressing the meq isoforms might
behave differently.
All recombinant viruses were successfully transmitted to contact chickens (Fig 3A), but
only contact chickens in the higher virulent meq isoform groups showed clinical signs and
tumors (Fig 3B and 3C). The tumor dissemination was also altered upon insertion of the dif-
ferent meq isoforms. While the vMeq tumors were only localized in one organ (spleen), multi-
ple organs were affected with the higher virulent meq viruses (Fig 2D). We found the highest
number of tumors in the vv+Meq group (Fig 2D) and observed the same trend of tumor dis-
semination in the contact chickens (Fig 3D). Importantly, experimentally and contact birds
were hatched on the same day and housed together for the duration of the experiment. There-
fore, the contact animals were infected much later (~ day 14) when they were already more
resistant to MDV. However, our results clearly show that the higher virulent meq isoforms
allow tumor formation in more organs in unvaccinated hosts.
In the next animal experiment, we aimed to assess the ability of the different recombinant
viruses to break the vaccinal protection and promote efficient horizontal spread. We vacci-
nated chickens with the HVT vaccine that protects chickens from vMDV (Fig 1A). We then
challenged the chickens at day seven post-vaccination using the viruses that harbor the differ-
ent meq isoforms. All viruses replicated efficiently in the vaccinated chickens (Fig 4A and 4B).
We observed no mortalities in groups infected with the less virulent meq viruses, as observed
with the parental strains that cannot overcome the HVT protection (Fig 4C).
The only birds that succumbed to disease despite vaccination were the birds challenged
with the higher virulent meq isoforms (Fig 4C). However, only the virus harboring the vv
+Meq was able to induce tumors in the vaccinated animals. It is remarkable that the virus only
required five distinct point mutations in the vv+Meq, allowing the vv+Meq to overcome vacci-
nal protection and cause malignant tumors (Fig 4D). All of these mutations found in vv+Meq
reside in the transactivation domain and affect the number of PRRs. Since the PRRs exhibit a
transrepression effect, the mutations interrupt the number of PRRs and thereby influence the
transactivation activity of Meq [43]. Moreover, Meq functions in target cellular and viral gene
transactivation and the higher transactivation properties of vv+Meq could alter and increase
proliferation, mobility and apoptosis resistance of cells that develop tumors, perhaps through
the upregulation of adhesion molecules via vTR [44,45]. In addition, the chicken CD30, which
is discussed to be involved in MDV lymphomagenesis, has 15 potential binding sites for Meq
[46]. Thus, the enhanced transactivation of vv+Meq could also lead to CD30 overexpression,
favoring neoplastic transformation. The latter hypothesis is consistent with observation on
other oncogenic viruses such as Epstein-Barr virus and Kaposi’s sarcoma-associated herpesvi-
rus [47]. However, CD30 overexpression in MDV-induced tumors could not be confirmed in
follow-up studies [48].
Efficient virus transmission provides strong evolutionary advantages [49]. Here we found
that the mutations in meq had a strong influence on the amount of virus presence in the
feather follicles and on viral shedding into the environment. The higher virulent meq isoform
viruses were detected at higher levels in feather follicles compared to the less virulent meq iso-
forms (Fig 4E). Consequently, the levels of virus shedding of the higher virulent meq isoforms
were increased (Fig 4F), likely providing an evolutionary advantage for the virus. There are
two potential reasons for increased virus shedding: i) that the viruses harboring the higher vir-
ulent meq isoforms replicate better in the feather follicles or ii) that the increased number of
transformed cells that can travel to the skin facilitate a more efficient delivery to the feather fol-
licles, enhancing virus production and shedding [50]. Read et al. recently demonstrated that
vaccination with leaky vaccines prolongs viral shedding and onward transmission of vv+MDV
strains as the host is kept alive for extended periods [5]. Also, they showed that the cumulative
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shedding of less virulent strains is reduced by vaccination, but increased by several orders of
magnitude with highly virulent strains [5].
It would be interesting to evaluate virus competition between the meq isoforms to determine
which virus sheds at higher rates as performed previously by Dunn et al [51]. They show for patho-
genically similar (rMd5 and rMd5/pp38CVI) or dissimilar (JM/102W and rMd5/pp38CVI) virus
pairs that the higher virulent strains had a competitive advantage over the less virulent strains [51].
The meq isoforms we chose are representative of a broad range of viruses and pathotypes
[52]. We did test two meq isoforms from the vMDV pathotype, JM102 (Figs 1–5) and 617A
(S1 Fig) that behaved similar, resulting in lower disease and tumor incidence compared to
viruses harboring a vv and vv+ meq. However, it would be interesting to test additional meq
isoforms from the respective pathotypes in future studies.
Nonetheless, our data indicate that the minor mutations in meq contribute to this enhanced
shedding that increases the level of infectious virus in the environment and provides a selective
advantage for more virulent strains.
Next, we turned to the first line of defense against MDV, the innate immunity. It has been
previously shown that Meq blocks apoptosis and interferes with antiviral activity [53,54]. As
Meq regulates viral and host genes, we evaluated whether the individual meq isoforms affect
cellular innate immune responses. The lower virulent meq isoforms showed a significant
reduction in growth and plaque sizes in cells treated with the agonists (Fig 5). In contrast, the
higher virulent meq isoforms allow the virus to overcome the antiviral response activated in
primary T cells stimulated by Poly I:C-, LPS- and cGAMP (Fig 5). It has been previously
shown that MDV has the ability to evade the cGAS-STING DNA sensing pathway (stimulated
by cGAMP) as Meq delayed the recruitment of TANK-binding kinase one and (interferon)
IFN regulatory factor 7 (IRF7) to the STING complex, thereby inhibiting IRF7 activation and
IFN-β induction [33]. Especially the vv and vv+meq isoforms were able to block the cGAS-ST-
ING DNA sensing pathway, as compared to the lower virulent meq isoforms (Fig 5). It remains
unclear how Meq mechanistically modulates the signaling pathway and should be investigated
to understand the role of Meq in the innate immunity in the future. Overall, our findings sug-
gest that the mutations in the higher virulent meq isoforms provide an advantage in the vacci-
nated animals by allowing the virus to overcome these innate responses early upon infection.
In summary, our data demonstrate that minor polymorphisms in meq drastically alter disease
outcomes in naïve and vaccinated chickens. The meq isoforms from highly virulent MDV strains
are required for efficient disease and tumor formation, while those from less virulent strains
severely impair or abrogate disease and tumor incidence. Also, we show that the mutations that
arose in the meq from higher virulent strains permitted vaccine resistance and the ability to shed
at higher rates in the environment; all factors promote the evolution of this pathogen.
Materials and methods
Ethics statement
All animal work was conducted in compliance with relevant national and international guide-
lines for care and humane use of animals. Animal experimentation was approved by the Land-
esamt für Gesundheit und Soziales in Berlin, Germany (approval numbers G0294-17 and
T0245-14) and the Agricultural Animal Care and Use Committee protocol (64R-2019-0, UBC
protocol 16–023).
Cells and viruses
CEC were prepared from 11-day old specific-pathogen-free (SPF) chicken embryos (VALO
BioMedia, Germany) as described previously [55]. CEC were cultured in Eagle’s minimal
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essential medium (MEM; PAN Biotech, Germany) supplemented with 10% fetal bovine serum
and antibiotics (100 U/mL penicillin and 100 μg/mL streptomycin). Reticuloendotheliosis
virus-transformed T cells (CU91) were propagated in RPMI 1640 media (PAN Biotech, Ger-
many) supplemented with 1% sodium pyruvate, 1% nonessential amino acids, 10% FBS, and
penicillin–streptomycin, and maintained at 41˚C in a 5% CO2 atmosphere. Viruses were
reconstituted by transfecting bacterial artificial chromosome (BAC) DNA into CEC as
described previously [55]. Viruses were propagated on CEC for four passages thereafter virus
stocks were frozen in liquid nitrogen and titrated on CEC as described previously [56,57].
Generation of recombinant viruses
To generate recombinant viruses that harbor meq isoforms from the different pathotypes, we
inserted the meq isoforms into the very virulent RB-1B strain (GenBank accession no.
MT797629) instead of the native meq gene as described previously [28]. This resulted in the
viruses containing the meq isoforms from CVI988/Rispens vaccine (vacMeq), vMDV strain
JM/102W (vMeq), vvMDV strain RB-1B (vvMeq) and vv+MDV N-strain (vv+Meq). Primers
used for mutagenesis are listed in Table 1. Insertions of the meq genes were confirmed by
Table 1. Primers and probes used for construction of recombinant viruses, DNA sequencing and qPCR.
Construct/
target






















ICP4 (qPCR) rev TCCCATACCAATCCTCATCCA
probe FAM-CCCCCACCAGGTGCAGGCA-TAM

















afor, forward primer; rev, reverse primer.
bFAM, 6-carboxyfluorescein; TAM, TAMRA.
https://doi.org/10.1371/journal.ppat.1009104.t001
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PCR, restriction fragment length polymorphism (RFLP), Sanger- and Illumina MiSeq
sequencing with a ~1000-fold coverage to ensure that the entire virus genome is correct. The
GenBank accession numbers for each meq isoform and resultant recombinant viruses can be
found in S1 Table.
Plaque size assays
Replication properties of the recombinant viruses were analyzed by plaque size assays as previ-
ously described [58]. Briefly, one million CEC were infected with 100 plaque-forming units
(pfu) of the recombinant viruses and cells were fixed at five dpi. Images of randomly selected
plaques (n = 50) were captured and plaque areas were determined using Image J software
(NIH, USA). Plaque diameters were calculated and compared to the respective control.
In vitro replication
In vitro replication of recombinant viruses was measured over six days by qPCR as previously
described [59,60]. Briefly, primers and probes specific for MDV-infected cell protein 4 (ICP4)
and chicken inducible nitric oxide synthase (iNOS) genes were used (Table 1). The qPCR anal-
ysis was performed using an ABI Prism 7700 Sequence Detection System (Applied Biosystems
Inc., USA) and the results were analyzed using the Sequence Detection System v.1.9.1 software.
Virus genome copies were normalized against the chicken iNOS gene as published previously
[50].
Quantitative reverse transcription PCR (RT-qPCR) and RT-PCR
To assess the expression levels of the meq isoforms we performed RT-qPCR as previously
described [61]. Briefly, total RNA was extracted from virus-infected CEC and CU91 using the
RNeasy Plus minikit (Qiagen) according to the manufacturer’s instructions. The samples were
treated with DNase I (Promega), and cDNA was generated using the High-Capacity cDNA
reverse transcription kit (Applied Biosystems).
ICP4 and GAPDH were used to control for the infection levels and the number of cells (S3
Fig). meq expression levels were normalized to the expression levels cellular GAPDH (per mil-
lion GAPH copies). The primers and probes used for RT-qPCR are shown in Table 1. To
investigate the expression of the meq/vIL8 splice form in cells infected with the recombinant
viruses, we performed RT-qPCR using primers specific for the meq/vIL8 splice variant as pre-
viously described [57].
In vivo characterization of recombinant viruses
Animal experiment 1 (pathogenesis of recombinant viruses). One-day old VALO SPF
chickens (VALO BioMedia) were randomly distributed into four groups and housed sepa-
rately. Chickens were infected subcutaneously with 4,000 pfu of vacMeq (n = 25), vMeq
(n = 23), vvMeq (n = 24) and vv+Meq (n = 25). With each group, 11 non-infected contact ani-
mals, same age, were housed to assess the natural transmission of the respective viruses. The
experiment was performed in a blinded manner to avoid bias. Animals were kept under a 12 h
light regime in stainless steel cages with wood and straw litter. Enrichment was provided by
perches, sand baths and picking stones. Rooms were air-conditioned and temperature was reg-
ulated starting from an air temperature of 28˚C on day 1 decreasing to 20˚C on day 21. In the
first 10 days, heat lamps were provided. Food and water were provided ad libitum. Whole
blood samples were collected for infected animals at 4, 7, 10, 14, 21 and 28 dpi and for contact
animals at day 21, 28, 35 and 42 to measure virus load in the blood. The chickens were assessed
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every day to monitor for MDV-specific clinical symptoms that include severe ataxia, paralysis,
torticollis and somnolence. If symptoms appeared, chickens were humanely euthanized and
examined for gross tumor lesions. Tumors were also assessed in chickens that did not show
Marek’s disease signs upon termination of the experiment at 85 dpi. DNA was isolated from
spleens and tumors to confirm the sequence of the inserted meq gene and integrity of the viral
genome. The phenotypes of the meq isoforms were confirmed in a second, independent ani-
mal experiment. White leghorn chickens (Sunrise Farms, Inc., Catskill, NY) were inoculated
with 1,000 PFU of the respective recombinant viruses (n = 18).
Animal experiment 2 (infection of vaccinated animals). One-day old VALO SPF chick-
ens were randomly distributed into four groups as described for animal experiment 1. Chick-
ens were subcutaneously vaccinated with 4,000 pfu of the HVT vaccine (strain FC 126;
Poulvac; Zoetis Inc., USA) for each group of 25 chickens. At seven days post-vaccination,
chickens were challenged with 5,000 pfu of vacMeq (n = 25), vMeq (n = 25), vvMeq (n = 23)
and vv+Meq (n = 25) and similar experimental procedures were followed as in animal experi-
ment 1. Whole blood samples were collected to measure virus load in the blood as described
above. Feathers were collected at 7, 10, 14, 21 and 28 dpi to monitor the time and the concen-
tration of the viruses that reached the feather follicles to be shed into the environment. Dust
shed from the infected chickens was collected from filters of each room once a week to assess
the shedding rates until termination of the experiment at 90 dpi. DNA was isolated from
spleens and tumors to confirm the sequence of the inserted meq genes.
Extraction of DNA from blood, feathers and dust
DNA was isolated from blood samples of infected and contact chickens using the E-Z96 blood
DNA kit (OMEGA Biotek, USA) according to the manufacturer’s instructions. Feathers were
collected from birds and the proximal ends of each feather containing the feather pulp
(referred to as feather tip). In addition, dust samples (three 1-mg aliquots) were collected from
the filters in each room at indicated time points. DNA was extracted from feathers and dust
samples as previously described [62]. All samples were analyzed by qPCR. The primers and
probes (Table 1) for the differential quantification between MDV and HVT were described
previously [63,64]. Briefly, the meq gene and SORF1 that are exclusively encoded in MDV and
HVT respectively were used as targets in the qPCR.
DNA extraction from organs and tumor tissue
The innuSPEED tissue DNA Kit (Analytik Jena) was used to extract DNA from organs,
according to the manufacturer’s instructions. Briefly, 50 mg of tissue were homogenized. The
homogenate was treated with RNase A and proteinase K digestion, with the exception to the
protocol, that proteinase K treatment was extended to 90 min to release viral DNA from the
nucleocapsids. The lysate was cleared by addition of a protein-denaturing buffer following
high speed centrifugation. The DNA in the supernatant was isolated on DNA binding col-
umns. After subsequent washing steps, the DNA was eluted in 150 μl elution buffer and used
for qPCR or next-generation sequencing analyses.
Next-generation sequencing of recombinant viruses
DNA sequencing of the recovered viruses and DNA from tumors and spleens were performed
on an Illumina MiSeq platform as previously described [65]. Briefly, one to five micrograms of
total DNA extracted were fragmented to a peak fragment size of 500–700 base pairs (bp). The
fragmented DNA (100 ng to 1 μg) was subjected to next-generation sequencing library prepa-
ration using the NEBNext Ultra II DNA Library Prep Kit for Illumina platforms (New England
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Biolabs). The bead-based size selection step was performed with Agencourt AMPure XP mag-
netic beads (Beckman Coulter Life Sciences) selecting for inserts of 500–700 bp. To achieve a
library yield >500 ng, five PCR cycles were performed.
We used a tiling array method to enrich the viral sequences from the DNA extracts that
were harvested from organs or tumors that contained mainly sequences of chicken origin [65].
The array contained 6,597 biotinylated RNA 80-mers that were designed against the sequence
of the RB-1B strain (MYcroarray; Arbor Biosciences). The enrichment was performed accord-
ing to the manufacturer’s instructions.
Next-generation sequence data analysis
All Illumina reads were processed with Trimmomatic v.0.36 [66] and mapped against the RB-
1B strain using the Burrows-wheeler aligner v.0.7.12 [67]. The single nucleotide polymorphism
(SNPs) were assessed with FreeBayes v.1.1.0–3 [68]. The data were merged by position and
mutation using R v.3.2.3. The SNPs were additionally assessed and generated using Geneious
R11 software.
Quantification of virus genome copies
MDV genome copy numbers were determined by quantitative PCR (qPCR) with primers and
probes specific for either the HVT vaccine or meq isoform recombinant viruses, to distinguish
between the viruses from vaccination and infection (Table 1). Virus genome copies were nor-
malized against the chicken iNOS gene as published previously [50]. The qPCR analysis on
feathers and dust was performed as described previously [5,69]. Briefly, for the feather tip sam-
ples, viral DNA copies were quantified as genomes per 104 feather tips and for dust, genomes
per microgram of dust (MDV genomes/mg dust; based on the mass of dust used to prepare
DNA and the volume of dust DNA used per reaction).
Assessment of virus spread and replication upon treatment with innate
immune agonists
Next, we determined if meq isoforms allow the virus to overcome cellular innate immune
responses in primary T cells. Primary T cells were extracted from the thymus of 12-day old
chickens as previously described [70]. T cells were stimulated with either LPS (5 μg/ml), Poly I:
C (100 ng/ml), and cGAMP (100 ng/ml), and control (medium only) to induce innate immune
responses. At six hours (h) post-activation, T cells were infected with the different meq isoform
viruses harboring a GFP reporter by co-cultivation with infected CEC due to the strict cell-
associated nature of MDV. At 24 h post-infection, viable infected GFP-expressing T cells were
isolated by FACS, and 1,000 infected cells were seeded on a fresh CEC monolayer. The number
of plaques and plaque sizes were determined at five dpi as described above.
Statistical analyses
Statistical analyses were performed using Graph-Pad Prism v7 (GraphPad Software, Inc.,
USA) and the SPSS software (SPSS Inc., USA). The multi-step growth kinetics were analyzed
with the Kruskal–Wallis test. Analysis for plaque size assays included a one-way analysis of
variance (ANOVA). Kaplan-Meier disease incidence curves were analyzed using the log-rank
test (Mantel-Cox test), and Fisher’s exact test was used for tumor incidences and distribution
with Bonferroni corrections on multiple comparisons. Tukey’s multiple comparisons test was
used for the analysis of feather and dust samples and for the innate immunity experiments.
Data were considered significant if p<0.05.
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Supporting information
S1 Fig. Pathogenesis in animals infected with meq recombinant viruses. (A) Disease inci-
dence of chickens infected with the indicated recombinant viruses and (B) tumor incidence as
percentage of animals that developed tumors during the experiment. Asterisks indicate signifi-
cant differences compared to vvMeq (� p<0.05 and �� p<0.0125; Fisher’s exact test).
(TIF)
S2 Fig. Next-generation sequencing of recombinant viruses. (A) The recombinant BACs
generated only harbored the natural mutations in meq of the different meq isoforms inserted
in the RB-1BΔIRL. (B) The recovered recombinant viruses in cell culture (passage 4) had no
secondary mutations in the genome. Both copies of meq are present, as the IRL is restored. (C)
Three representative samples from each recombinant virus from organs or tumor samples
were extracted and sequenced. The sequences were aligned with the respective recombinant
virus from passage 4. No mutations were detected in meq, and only minor point mutations in
the minority of the viruses as summarized.
(TIFF)
S3 Fig. RT-qPCR analysis in vitro. The viral ICP4 (A) and cellular GAPDH (B) expression
levels were used to control for the infections and the number of cells respectively. Viral ICP4
copies (A) and cellular GAPDH (B) were assessed by RT-qPCR and were not statistically dif-
ferent (p> 0.05, Kruskal-Wallis test).
(TIF)
S1 Table. meq genes from different MDV pathotypes and genomic sequences from all
viruses used in this study.
(DOCX)
S2 Table. Meq protein sequence alignments from infected animals.
(DOCX)
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